title: Treatment goals for psoriasis: Should PASI 90 become the standard of care?
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal. Electronic address: tiagotorres2002@hotmail.com.
authors.forename: T
authors.initials: T
authors.lastname: Torres
authors.affiliation: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Puig
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006040:Goals; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents